Zacks Research Comments on Pfizer’s Q1 Earnings (NYSE:PFE)

Pfizer Inc. (NYSE:PFE) – Zacks Research upped their Q1 2025 earnings per share estimates for shares of Pfizer in a research note issued to investors on Monday, February 24th. Zacks Research analyst K. Shah now expects that the biopharmaceutical company will earn $0.63 per share for the quarter, up from their prior estimate of $0.61. The consensus estimate for Pfizer’s current full-year earnings is $2.95 per share. Zacks Research also issued estimates for Pfizer’s Q2 2025 earnings at $0.58 EPS, Q4 2025 earnings at $0.82 EPS, Q1 2026 earnings at $0.63 EPS and Q2 2026 earnings at $0.58 EPS.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter in the prior year, the firm posted $0.10 EPS. Pfizer’s quarterly revenue was up 24.7% compared to the same quarter last year.

Other equities analysts have also recently issued research reports about the company. Guggenheim reissued a “buy” rating and set a $33.00 target price on shares of Pfizer in a report on Monday, February 10th. Truist Financial reduced their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Bank of America reissued a “neutral” rating and set a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Finally, UBS Group cut their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Price Performance

Shares of Pfizer stock opened at $26.43 on Thursday. The business has a 50 day simple moving average of $26.35 and a two-hundred day simple moving average of $27.34. Pfizer has a 12 month low of $24.48 and a 12 month high of $31.54. The stock has a market capitalization of $149.78 billion, a P/E ratio of 18.74, a PEG ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Institutional Trading of Pfizer

Several hedge funds have recently modified their holdings of PFE. Swedbank AB raised its stake in shares of Pfizer by 0.7% in the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock valued at $166,284,000 after acquiring an additional 37,636 shares in the last quarter. Pallas Capital Advisors LLC raised its stake in shares of Pfizer by 54.8% in the third quarter. Pallas Capital Advisors LLC now owns 25,711 shares of the biopharmaceutical company’s stock valued at $736,000 after acquiring an additional 9,102 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Pfizer by 132.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 20,361 shares of the biopharmaceutical company’s stock valued at $589,000 after buying an additional 11,615 shares in the last quarter. Integrated Advisors Network LLC raised its stake in Pfizer by 18.3% in the third quarter. Integrated Advisors Network LLC now owns 64,014 shares of the biopharmaceutical company’s stock valued at $1,853,000 after buying an additional 9,925 shares in the last quarter. Finally, Fidelis Capital Partners LLC raised its stake in Pfizer by 5.2% in the third quarter. Fidelis Capital Partners LLC now owns 25,835 shares of the biopharmaceutical company’s stock valued at $746,000 after buying an additional 1,267 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction dated Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.06% of the company’s stock.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a dividend of $0.43 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.51%. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is currently 121.99%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.